Clinical Strategies for PARP Inhibitors beyond Homologous Recombination Deficiency

recurrent ovarian cancer and today there are already three PARP inhibitors approved; olaparib, rucaparib and niraparib. PARP inhibitors selectively target cancers with mutation of BRCA1 or BRCA2 alleles owing to their homologous recombination deficiency (HRD).

Author(s): Thomas Helleday

Warning: Undefined variable $art_rows in /efsdata/imedpub-com/abstract/abstract-page.php on line 110

Warning: Attempt to read property "select_abs_row" on null in /efsdata/imedpub-com/abstract/abstract-page.php on line 110

Abstract | Full-Text | PDF

Share This Article